Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.5M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$177M |
Are Inhibikase Therapeutics Insiders Buying or Selling?
Inhibikase Therapeutics (IKT) has had no reported insider transactions in the past 90 days. The most recent was Sands Capital Alternatives, LLC, who bought 2,068,965 shares at $1.45 on November 21, 2025.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the IKT AI Score. For government officials trading this stock, see IKT congressional trading.
Recent Inhibikase Therapeutics Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Sands Capital Alternatives, LLC | Nov 21, 2025 | Buy | 2,068,965 | $1.45 | $3M |
| Roberto Bellini | Oct 21, 2024 | Buy | 1,460,000 | $1.37 | $2M |
| Arvind Kush | Oct 21, 2024 | Buy | 145,000 | $1.37 | $200,000 |
| Amit Munshi | Oct 21, 2024 | Buy | 365,000 | $1.37 | $500,000 |
Frequently Asked Questions: Inhibikase Therapeutics Insider Trading
Inhibikase Therapeutics insiders have not reported any transactions in the past 90 days.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Sands Capital Alternatives, LLC has bought the most IKT stock in the last 2 years, with a total value of $3M.
According to our estimates, the total value of insider transactions for Inhibikase Therapeutics in the last 2 years is positive, amounting to $5.7M. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
